Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Premera Blue Cross, a regional health plan, has agreed to cover its ThyraMIR test for more than 2 million members located primarily in Washington, Oregon, and Alaska.

Premera Blue Cross has a network of more than 38,000 physicians, hospitals, laboratories, and other healthcare providers across the Northwest, Interpace said.

Its ThyraMIR assay is covered for thyroid nodules deemed indeterminate by standard cytopathological analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.